Current Position, Affiliation
- Professor, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea
Education / Training
- 1995, M.D., Seoul National University Medical College
- 1999, M.S., Seoul National University Medical College
- 2006, PhD., Seoul National University Medical College
Professional and Research Experience
- 2000 - 2002, Public health doctor, Korean FDA
- 2004 - 2006, Postdoctoral fellowship, Division of Nephrology, University of Pennsylvania, USA
- 2010 - 2010, Visiting scholar, Tokyo Women's Medical University
- 2009 - 2021, Professor, Transplantation center, Seoul National University Hospital
- 2021 - Present, Professor, Division of Nephrology, Department of Internal Medicine, Yonsei University
Awards & Honors
- 2006, Young Investigator Award, the American Society of Transplantation
- 2008, New Key Opinion Leader Award, The Transplantation Society
- 2008, Young Investigator Award, Korean Society of Nephrology
- 2022, Academic Grand Award, the Korean Society for Transplantation
Selected Publications
- Han DK, Hong SK, Yun IH, Yan JJ, Park JS, Kim SW, Seok SH, Kim H, Ji G, Choi Y, Lee KW, Suh KS, Yang J, Yi NJ. Anti-ICAM-1 mono-maintenance therapy induced long-term liver allograft survival without chronic rejection. Am J Transplant 2024;24(10):1772-1783.
- Yoo EJ, Oh K-H, Piao Honglin, Kang HJ, Jeong GW, Park H, Lee CJ, Ryu H, Yang SH, Kim M-G, Kim DK, Park SH, Lim BJ, Lee SM, Park CY, Choi SY, Lee-Kwon W, Yang J, Kwon HM. Macrophage TonEBP promotes systemic lupus erythematosus and renal injury via damage-induced signaling pathways. Kidney Int 2023;104(1):163-180.
- Kim TH, Yang JJ, Jang JY, Lee GM, Lee SK, Kim BS, Chung JJ, Kim SH, Jung Y, Yang J. Tissue-Engineered Vascular Microphysiological Platform to Study Immune Modulation of Xenograft Rejection. Science Adv 2021;7(22):eabg2237.
- Koo TY, Lee JH, Min SI, Lee Y, Kim MS, Ha J, Kim SI, Ahn C, Kim YS, Kim J, Huh KH, Yang J. Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time. Kidney Int 2021;100(1):205-214.
- Yan JJ, Kim H, Kim B, Piao H, Jang JY, Kang TK, Lee WB, Kim D, Jo S, Shin D, Abuzar SM, Kim ML, Yang J, Jon S. Synthetic Bilirubin-Based Nanomedicine Protects Against Renal Ischemia/Reperfusion Injury Through Antioxidant and Immune-Modulating Activity. Adv Healthc Mater. 2025 Mar;14(7):e2403846.
Kidney Transplantation Beyond Current Perspective
Role
Speaker
Date & Time
12/06 11:10 - 11:25
Place
Room 5 ( 701G )
Lecture Title
Clinical Significance of Donor Quality for Predicting Long-term Post-transplant Outcomes